---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-097317"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:23:18.191904+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Novavax completes Nuvaxovid EU marketing authorization transfer to Sanofi; triggers $25M milestone

## Summary
- European Commission approved transfer of Nuvaxovid EU marketing authorization from Novavax CZ to Sanofi Winthrop Industrie.
- Milestone payment of $25M triggered; Novavax expects receipt in Q1 2026.
- Additional milestones: $25M for U.S. transfer, $75M for technology transfer, up to $350M for combo products.
- Novavax eligible for tiered royalties on Sanofi's standalone COVID vaccine and combination products.
- CEO John Jacobs: successful transfer is another step in ensuring global access to protein-based COVID vaccine.

## SEC filing metadata
- accession: 0001104659-25-097317
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925097317/0001104659-25-097317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925097317/tm2528134d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-097317
- JSON: https://secwatch.observer/filing/0001104659-25-097317.json
- Plain text: https://secwatch.observer/filing/0001104659-25-097317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.